Over the Counter, But Not Within Reach? Insurance Gaps and the Future of Birth Control Access

The recent approval of over-the-counter (OTC) oral contraceptives marks a significant shift in reproductive health policy. In July 2023, the FDA approved Opill (norgestrel 0.075 mg) as the first OTC daily oral contraceptive in the United States, with retail availability beginning in 2024. The approval of Opill is the first time a routine hormonal birth control pill could be purchased without a prescription, eliminating the need for a clinical visit. Approximately 45% of U.S. pregnancies are unintended, and consistent contraceptive access is important in reducing unintended pregnancy rates. OTC availability is intended to reduce logistical barriers, particularly for individuals who face challenges in accessing primary care or OB-GYN services.

However, this policy shift changes how coverage for contraception fits within the Affordable Care Act’s (ACA) preventive service mandate. 

The ACA preventative services mandate states that most health plans have to cover a set of preventative services–like screenings and vaccinations–at zero cost to the patient when provided by an in-network provider. This mandate also covers plans available through the Marketplace. The specific services included under the mandate are determined by federal expert bodies, including the U.S. Preventive Services Task Force (USPSTF), the Advisory COmmittee on Immunization Practices (ACIP), and the Health Resources and Services Administration (HRSA). For women’s health, HRSA’s guidelines require coverage of FDA-approved contractive methods, contraceptive counseling, and related follow-up services without cost-sharing. This framework is meant to reduce financial barriers to preventive care and promote early intervention, although coverage requirements apply only to non-grandfathered plans and can vary in implementation across insurers. 

Despite this federal framework, OTC status complicates the operationalization of zero-cost coverage. Historically, contraceptive coverage under the ACA has functioned through prescription-based reimbursement systems. This means that insurers would pay for at least one of the 18 FDA-approved contraceptive categories for women, including pills, IUDs, or rings. When contraception is dispensed directly from the pharmacy shelf, insurers must determine how to process claims without a traditional prescribing pathway. Although recent federal guidance proposes to strengthen the ACA requirements by compelling most groups' health plans to cover FDA approved OTC contraceptives without cost-sharing, the implementation remains a major hurdle. This statement from federal guidelines is just a suggestion, and is not currently legally binding. The implementation depends on insurer compliance and point-of-sale system. If reimbursement mechanisms are unclear or inconsistently applied, patients may be required to pay upfront and seek reimbursement later, weakening the promise of immediate, zero-cost access at the pharmacy counter.

Artwork by Shea Davis

Retail pricing of OTC contraception also shapes its level of accessibility. Research shows that cost is a major driver of OTC contraceptive use and continuation. A nationally representative analysis published in Contraceptive found that about 22% of women at risk of unintended pregnancy reported they would prefer to use a different contraceptive method if cost were not a barrier, showing that affordability plays a measurable role in whether women can use their preferred method. Because most private insurance plans have not traditionally covered OTC drugs without a prescription, patients who purchase OTC birth control often pay the full, retail price at the pharmacy counter. Although Opill is marketed at around $19.99 per month ($240 a year), that recurring cost still deters consistent use, particularly among students, lower-income individuals, and those enrolled in high-deductible plans.If OTC contraception is not consistently covered at the pharmacy counter and instead requires patients to pay upfront, the expansion of access may be more theoretical than practical. While the product is available without a prescription, it may still remain financially out of reach for many individuals who are most likely to benefit from it.

How OTC contraception is implemented will also significantly shape its impact on health equity. Nearly 19 million women in the United States live in contraceptive deserts–places where access to a health center offering the full range of contraceptive methods is limited. For individuals in rural areas, those without paid leave. For those seeking greater privacy, eliminating the need for clinical visits does reduce logistical burdens (physician appointment). At the same time, these populations are often the most affected by high out-of-pocket costs. Without consistent enforcement of zero-cost coverage, regulatory access may expand while financial access remains uneven. Ultimately, the approval of OTC birth control does represent a meaningful step toward residing clinical gatekeeping in reproductive health care. However, expanding pharmacy access alone doesn't guarantee equitable access. The public health impact of OTC contraception will depend on not only FDA approval, but also how effectively insurance coverage protections are implemented and reinforced. So, making birth control available over the counter only improves access if it is also consistently affordable.